Company Filing History:
Years Active: 2018
Title: Ian Stefanuti: Innovator in Pharmaceutical Chemistry
Introduction
Ian Stefanuti is a notable inventor based in High Peak, Great Britain. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific proteins involved in various diseases.
Latest Patents
Ian holds a patent for Aryl-cyanoguanidine compounds. This invention relates to inhibitors of protein-lysine N-methyltransferase SMYD2, which is crucial in the treatment of hyper-proliferative disorders, including cancer. The patent details the use of SMYD2-inhibitory substituted cyanoguanidine-pyrazolines, along with their pharmaceutical compositions and therapeutic applications for various disorders such as atherosclerosis, sepsis, and neurodegenerative diseases.
Career Highlights
Ian is currently employed at Bayer Pharma Aktiengesellschaft, where he continues to innovate and develop new therapeutic solutions. His work focuses on creating compounds that can effectively inhibit specific proteins, thereby providing new avenues for treatment in various medical conditions.
Collaborations
Ian collaborates with esteemed colleagues, including Jeffrey Stuart Mowat and Timo Stellfeld. These partnerships enhance the research and development efforts at Bayer, contributing to the advancement of pharmaceutical science.
Conclusion
Ian Stefanuti's work exemplifies the impact of innovative research in the pharmaceutical industry. His contributions to the development of SMYD2 inhibitors highlight the importance of targeted therapies in treating complex diseases.